Inclusion Criteria:

          1. Histologically confirmed synovial sarcoma

          2. Surgically unresectable tumor

          3. Progressing or recurrent synovial sarcoma which has been treated with 1-4 regimens of
             systemic chemotherapies including anthracycline

          4. HLA-A*02:01 or HLA-A*02:06 positive

          5. Tumor that express NY-ESO-1 by immunohistochemistry

          6. ≥ 18 years of age

          7. Measurable lesions that are evaluable by the RECIST ver1.1

          8. ECOG Performance Status of 0, 1 or 2

          9. No treatment such as chemotherapy and be expected to recover fully from the previous
             treatment at the time of the lymphocytes collection for manufacturing

         10. Life expectancy ≥ 16 weeks after consent

         11. No severe damage on the major organs (bone marrow, heart, lung, liver, kidney, etc)
             and meet the following lab value criteria; Total bilirubin ≤ 1.5 x upper limit of
             normal (ULN); AST(GOT), ALT(GPT) < 3.0 x ULN; Creatinine < 1.5 x ULN; 2,500/μL < WBC
             ≤ULN; Hemoglobin ≥ 8.0g/dL; Platelets ≥ 75,000/μL

         12. Patients must be able to understand the study contents and to give a written consent
             at his/her free will. Additionally, if patients are below 20 years of age, proxies
             must be able to give a written consent.

        Exclusion Criteria:

          1. Patients with the following conditions are excluded from the study; Unstable angina,
             cardiac infarction, or heart failure; Uncontrolled diabetes or hypertension; Active
             infection; Obvious interstitial pneumonia or lung fibrosis by chest X-ray; Active
             autoimmune disease requiring steroids or immunosuppressive therapy.

          2. Active metastatic tumor cell invasion into CNS

          3. Active multiple cancer

          4. Positive for HBs antigen or HBV-DNA observed in serum

          5. Positive for HCV antibody and HCV-RNA observed in serum

          6. Positive for antibodies against HIV or HTLV-1

          7. Left Ventricular Ejection Fraction (LVEF) ≤ 50%

          8. History of serious hypersensitivity reactions to bovine or murine derived substances.

          9. History of hypersensitivity reaction to ingredients or excipients of investigational
             drugs used in this study

         10. History of hypersensitivity reaction to antibiotics used in manufacturing for the
             investigational drug used in this study.

         11. Pregnant females, lactating females (except when they cease and do not resume
             lactation) or female and male patients who cannot agree to practice the adequate birth
             control from the consent to 6 months after infusion of the investigational drug.

         12. Clinically significant systemic illness that in the judgment of the PI or
             sub-investigator would compromise the patient's ability to tolerate protocol therapy
             or significantly increase the risk of complications.